Identifying individual T cell receptors of optimal avidity for tumor antigens
M Hebeisen, M Allard, PO Gannon, J Schmidt… - Frontiers in …, 2015 - frontiersin.org
Cytotoxic T cells recognize, via their T cell receptors (TCRs), small antigenic peptides
presented by the major histocompatibility complex (pMHC) on the surface of professional …
presented by the major histocompatibility complex (pMHC) on the surface of professional …
Trial watch: Peptide vaccines in cancer therapy
Prophylactic vaccination constitutes one of the most prominent medical achievements of
history. This concept was first demonstrated by the pioneer work of Edward Jenner, dating …
history. This concept was first demonstrated by the pioneer work of Edward Jenner, dating …
[HTML][HTML] TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell–related pathology
M Dziubianau, J Hecht, L Kuchenbecker… - American journal of …, 2013 - Elsevier
Clonotype analysis is essential for complete characterization of antigen-specific T cells.
Moreover, knowledge on clonal identity allows tracking of antigen-specific T cells in whole …
Moreover, knowledge on clonal identity allows tracking of antigen-specific T cells in whole …
LAG-3 and PD-1+ LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
N Gestermann, D Saugy, C Martignier, L Tillé… - …, 2020 - Taylor & Francis
Despite the success of immunotherapy using checkpoint blockade, many patients with solid
tumors remain refractory to these treatments. In human cancer, the experimental options to …
tumors remain refractory to these treatments. In human cancer, the experimental options to …
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity
P Baumgaertner, J Schmidt, CM Costa-Nunes… - Frontiers in …, 2022 - frontiersin.org
Recruitment and activation of CD8 T cells occur through specific triggering of T cell receptor
(TCR) by peptide-bound human leucocyte antigen (HLA) ligands. Within the generated …
(TCR) by peptide-bound human leucocyte antigen (HLA) ligands. Within the generated …
[HTML][HTML] TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency
M Allard, B Couturaud, L Carretero-Iglesia, MN Duong… - JCI insight, 2017 - ncbi.nlm.nih.gov
Despite influencing many aspects of T cell biology, the kinetics of T cell receptor (TCR)
binding to peptide-major histocompatibility molecules (pMHC) remain infrequently …
binding to peptide-major histocompatibility molecules (pMHC) remain infrequently …
Direct recognition of LPS drive TLR4 expressing CD8+ T cell activation in patients with rheumatoid arthritis
Aberrant immune responses characterize autoimmune disorders like Rheumatoid Arthritis
(RA) wherein lymphocytes are recognized as key players. Role of CD8+ T cells in RA has …
(RA) wherein lymphocytes are recognized as key players. Role of CD8+ T cells in RA has …
Molecular insights for optimizing T cell receptor specificity against cancer
M Hebeisen, SG Oberle, D Presotto… - Frontiers in …, 2013 - frontiersin.org
Cytotoxic CD8 T cells mediate immunity to pathogens and they are able to eliminate
malignant cells. Immunity to viruses and bacteria primarily involves CD8 T cells bearing high …
malignant cells. Immunity to viruses and bacteria primarily involves CD8 T cells bearing high …
High peptide dose vaccination promotes the early selection of tumor antigen-specific CD8 T-cells of enhanced functional competence
L Carretero-Iglesia, B Couturaud… - Frontiers in …, 2020 - frontiersin.org
CD8 T-cell response efficiency critically depends on the TCR binding strength to peptide-
MHC, ie, the TCR binding avidity. A current challenge in onco-immunology lies in the …
MHC, ie, the TCR binding avidity. A current challenge in onco-immunology lies in the …
Rapid and continued T-cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients
PO Gannon, P Baumgaertner, A Huber, EM Iancu… - Clinical Cancer …, 2017 - AACR
Purpose: Patients with cancer benefit increasingly from T-cell–based therapies, such as
adoptive T-cell transfer, checkpoint blockade, or vaccination. We have previously shown that …
adoptive T-cell transfer, checkpoint blockade, or vaccination. We have previously shown that …